Evelina Carapancea
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Evelina Carapancea has a total of 198 co-authors. Here are the top co-authors by number of shared publications:
- Maria Roberta Cilio
Institute of Neuroscience Université catholique de Louvain Brussels Belgium
8 shared publications - Damien Lederer
Centre de Génétique Humaine Institut de Pathologie et de Génétique Gosselies Belgium
3 shared publications - Renzo Guerrini
Neuroscience and Human Genetics Department, Meyer Children's Hospital IRCCS, Florence, Italy
3 shared publications - Sarah Weckhuysen
Translational Epilepsy Genomics Group, VIB Center for Molecular Neurology, VIB
3 shared publications - Barbara Castellotti
Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy
2 shared publications - Gaetan Lesca
Department of Medical Genetics, University Hospital of Lyon, Claude Bernard University Lyon 1, Lyon, France
2 shared publications
Latest Publications
- Open Access
Long-read genome sequencing resolves complex structural variants in exome-negative developmental and epileptic encephalopathy
Background and Objectives: Developmental and Epileptic Encephalopathies (DEEs) encompass a clinically and molecularly heterogeneous group of mainly genetic disorders. Despite standard genetic testing, approximately two-thirds of patients remain undiagnosed. Pathogenic noncoding and structural variants (SVs), particularly complex rearrangements that are difficult to detect or resolve using short-read sequencing, may contribute to this diagnostic gap. To evaluate the diagnostic contribution of long-read genome sequencing (lrGS), we recruited a cohort of 124 families with sporadic DEE who remained unsolved by prior ES. Methods: Trio lrGS (Oxford Nanopore or PacBio HiFi) was performed, complemented zby short-read genome sequencing (srGS) and mRNA sequencing (blood or fibroblast) of index cases, where available. Comprehensive variant analysis included small nucleotide variants (SNVs), indels, SVs, and short tandem repeats. To identify the diagnostic yield of each method, we compared lrGS, srGS and ES re-analysis, and evaluated the additional value of RNA sequencing. Results: We established a diagnosis in 21 of 124 families (16.9%). Fourteen variants were retrospectively detectable in prior ES., Two cases with non-coding variants in SCN1A and RNU2-2 were detectable by both srGS and lrGS. Five SVs also required genome sequencing (5.6% of the total cohort), three of which could be detected, but not confidently resolved by srGS due to breakpoint complexity, repeat-mediated rearrangements, and large copy-neutral events: LrGS enabled accurate characterization of Alu-mediated CDKL5 and STXBP1 deletions and a MEF2C deletion with large inversion. A copy-neutral SCN1A inversion was well characterizable by both srGS and lrGS. One balanced translocation t(X;17) disrupting CDKL5 was resolved by lrGS (srGS unavailable). RNA sequencing confirmed pathogenicity of two SVs including t(X;17), the MEF2C deletion with inversion, and two CNVs. In addition, ZNF569 and ZNF570 emerged as candidate epilepsy genes from our cohort. Discussion: In ES-negative DEE, the incremental diagnostic yield of genome sequencing was modest, while lrGS provided particular value for the structural resolution of complex rearrangements, especially those involving repetitive sequences. The finding that two-thirds of diagnoses were retrospectively detectable in prior ES highlights the substantial value of systematic reanalysis. Further gains from genome sequencing may increasingly depend on improved interpretation of non-coding variation and integration of long-read-specific information. Our findings indicate that complex SVs represent the class for which lrGS currently yields the most distinctive diagnostic information.
Open AccessLong-read genome sequencing resolves complex structural variants in exome-negative developmental and epileptic encephalopathy
Background and Objectives: Developmental and Epileptic Encephalopathies (DEEs) encompass a clinically and molecularly heterogeneous group of mainly genetic disorders. Despite standard genetic testing, approximately two-thirds of patients remain undiagnosed. Pathogenic noncoding and structural variants (SVs), particularly complex rearrangements that are difficult to detect or resolve using short-read sequencing, may contribute to this diagnostic gap. To evaluate the diagnostic contribution of long-read genome sequencing (lrGS), we recruited a cohort of 124 families with sporadic DEE who remained unsolved by prior ES. Methods: Trio lrGS (Oxford Nanopore or PacBio HiFi) was performed, complemented zby short-read genome sequencing (srGS) and mRNA sequencing (blood or fibroblast) of index cases, where available. Comprehensive variant analysis included small nucleotide variants (SNVs), indels, SVs, and short tandem repeats. To identify the diagnostic yield of each method, we compared lrGS, srGS and ES re-analysis, and evaluated the additional value of RNA sequencing. Results: We established a diagnosis in 21 of 124 families (16.9%). Fourteen variants were retrospectively detectable in prior ES., Two cases with non-coding variants in SCN1A and RNU2-2 were detectable by both srGS and lrGS. Five SVs also required genome sequencing (5.6% of the total cohort), three of which could be detected, but not confidently resolved by srGS due to breakpoint complexity, repeat-mediated rearrangements, and large copy-neutral events: LrGS enabled accurate characterization of Alu-mediated CDKL5 and STXBP1 deletions and a MEF2C deletion with large inversion. A copy-neutral SCN1A inversion was well characterizable by both srGS and lrGS. One balanced translocation t(X;17) disrupting CDKL5 was resolved by lrGS (srGS unavailable). RNA sequencing confirmed pathogenicity of two SVs including t(X;17), the MEF2C deletion with inversion, and two CNVs. In addition, ZNF569 and ZNF570 emerged as candidate epilepsy genes from our cohort. Discussion: In ES-negative DEE, the incremental diagnostic yield of genome sequencing was modest, while lrGS provided particular value for the structural resolution of complex rearrangements, especially those involving repetitive sequences. The finding that two-thirds of diagnoses were retrospectively detectable in prior ES highlights the substantial value of systematic reanalysis. Further gains from genome sequencing may increasingly depend on improved interpretation of non-coding variation and integration of long-read-specific information. Our findings indicate that complex SVs represent the class for which lrGS currently yields the most distinctive diagnostic information.
- 29 August 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 142, 230-239
Phenotype-driven response to sodium channel blockers in neonatal and infantile genetic epilepsies with tonic seizures
- 29 August 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 142, 230-239
Phenotype-driven response to sodium channel blockers in neonatal and infantile genetic epilepsies with tonic seizures
- 10 August 2026
- Published by Wiley in Developmental Medicine & Child Neurology
Diagnostic delay in infants with very early‐onset rare and ultra‐rare genetic epilepsies
Aim: To evaluate time to diagnosis in infants with very early‐onset genetic epilepsies, identify contributing factors to diagnostic delay, and assess the impact of a definite diagnosis on clinical management. Method: Infants with genetic epilepsies and seizure onset before 3 months of age were retrospectively identified from a cohort of 500 children with epilepsy followed at Saint‐Luc University Hospital, Belgium, between 2018 and 2025. A correct diagnosis was defined as recognition of electroclinical phenotype before or at genetic confirmation. Diagnostic delay was defined as time to diagnosis exceeding 4 weeks from seizure onset. Results: Thirty infants with KCNQ2/3‐, SCN2A‐, SCN1A gain‐of‐function, CDD‐, BRAT1‐, KCNT1‐, FGF12‐, SMC1A‐, STXBP1‐, GNAO1‐, PHF6‐, CELF2 ‐ , and 2q24.3 microduplication‐related epilepsies were included. Median time to diagnosis was 55 days (interquartile range 30–427). Twenty‐four patients (80%) experienced more than 4 weeks' delay. The correct diagnosis prompted change in management in 25 infants (83%). Contributing factors included deferred diagnosis by paediatric neurologists (79%), unreported/undescribed phenotypes in ultra‐rare epilepsies (33%), misinterpretation of ictal events by paediatricians (17%), and parental underestimation of events (13%). Interpretation: Diagnostic delay in infants with rare epilepsies is a major issue, even in a universal health care context, mainly driven by mischaracterization of seizure semiology by paediatric neurologists.
- 10 August 2026
- Published by Wiley in Developmental Medicine & Child Neurology
Diagnostic delay in infants with very early‐onset rare and ultra‐rare genetic epilepsies
Aim: To evaluate time to diagnosis in infants with very early‐onset genetic epilepsies, identify contributing factors to diagnostic delay, and assess the impact of a definite diagnosis on clinical management. Method: Infants with genetic epilepsies and seizure onset before 3 months of age were retrospectively identified from a cohort of 500 children with epilepsy followed at Saint‐Luc University Hospital, Belgium, between 2018 and 2025. A correct diagnosis was defined as recognition of electroclinical phenotype before or at genetic confirmation. Diagnostic delay was defined as time to diagnosis exceeding 4 weeks from seizure onset. Results: Thirty infants with KCNQ2/3‐, SCN2A‐, SCN1A gain‐of‐function, CDD‐, BRAT1‐, KCNT1‐, FGF12‐, SMC1A‐, STXBP1‐, GNAO1‐, PHF6‐, CELF2 ‐ , and 2q24.3 microduplication‐related epilepsies were included. Median time to diagnosis was 55 days (interquartile range 30–427). Twenty‐four patients (80%) experienced more than 4 weeks' delay. The correct diagnosis prompted change in management in 25 infants (83%). Contributing factors included deferred diagnosis by paediatric neurologists (79%), unreported/undescribed phenotypes in ultra‐rare epilepsies (33%), misinterpretation of ictal events by paediatricians (17%), and parental underestimation of events (13%). Interpretation: Diagnostic delay in infants with rare epilepsies is a major issue, even in a universal health care context, mainly driven by mischaracterization of seizure semiology by paediatric neurologists.
- Open Access
- 11 June 2026
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 62, 61-75
Climate change and neurological disorders in childhood: A scoping review
- 11 June 2026
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 62, 61-75
Open AccessClimate change and neurological disorders in childhood: A scoping review
- Open Access
Predictive value of seizure onset for gross motor dysfunction in individuals with pathogenic GABRB2 and GABRB3 variants
Objective: Pathogenic variants in γ‐aminobutyric acid type A (GABA A ) receptor genes have been associated with a wide spectrum of neurological disorders. We aimed to delineate the clinical trajectories associated with gain‐of‐function (GoF) and loss‐of‐function (LoF) variants in GABRB2 and GABRB3 , and to develop a risk‐prediction model for gross motor dysfunction based on age at seizure onset. Methods: Clinical data, including seizure onset, epilepsy syndromes, cognitive outcomes, and gross motor function classification system (GMFCS), were collected through direct interviews, physician reports, and literature review. Kruskal–Wallis, Mantel–Cox and non‐parametric analysis of variance (ANOVA) with Dunn's corrected post hoc tests were used for statistical comparisons. A logistic ordinal regression model was developed to predict GMFCS outcomes based on age at seizure onset. Results: We analyzed a cohort of 117 individuals with pathogenic GABRB2 ( n = 49) and GABRB3 ( n = 68) variants. Fifty‐three individuals carried GoF variants and 64 carried LoF variants. The GoF group was associated with earlier seizure onset, higher seizure frequency, and lower rates of seizure freedom. Gross motor dysfunction was markedly worse in the GoF group, with 64% classified as GMFCS IV or V (non‐ambulation), compared to 7.5% in the LoF group. An inverse correlation was found between age at seizure onset and GMFCS severity in the GoF, but not the LOF group. The risk model predicted a >90% likelihood of non‐ambulation for individuals with GoF variants and seizure onset before 1 month of age, decreasing to ~35% with seizure onset after 20 months. Significance: We found a clear genotype–phenotype correlation in GABRB2‐ and GABRB3 ‐related disorders, demonstrating that GoF variants are associated with a more severe neurodevelopmental trajectory. The age at seizure onset serves as a biomarker for predicting motor outcomes in individuals with GoF variants. These findings provide guidance regarding prognosis, need for early intervention, and data for comparison of efficacy in targeted therapeutic interventions for GABA A receptor–related disorders.
Open AccessPredictive value of seizure onset for gross motor dysfunction in individuals with pathogenic GABRB2 and GABRB3 variants
Objective: Pathogenic variants in γ‐aminobutyric acid type A (GABA A ) receptor genes have been associated with a wide spectrum of neurological disorders. We aimed to delineate the clinical trajectories associated with gain‐of‐function (GoF) and loss‐of‐function (LoF) variants in GABRB2 and GABRB3 , and to develop a risk‐prediction model for gross motor dysfunction based on age at seizure onset. Methods: Clinical data, including seizure onset, epilepsy syndromes, cognitive outcomes, and gross motor function classification system (GMFCS), were collected through direct interviews, physician reports, and literature review. Kruskal–Wallis, Mantel–Cox and non‐parametric analysis of variance (ANOVA) with Dunn's corrected post hoc tests were used for statistical comparisons. A logistic ordinal regression model was developed to predict GMFCS outcomes based on age at seizure onset. Results: We analyzed a cohort of 117 individuals with pathogenic GABRB2 ( n = 49) and GABRB3 ( n = 68) variants. Fifty‐three individuals carried GoF variants and 64 carried LoF variants. The GoF group was associated with earlier seizure onset, higher seizure frequency, and lower rates of seizure freedom. Gross motor dysfunction was markedly worse in the GoF group, with 64% classified as GMFCS IV or V (non‐ambulation), compared to 7.5% in the LoF group. An inverse correlation was found between age at seizure onset and GMFCS severity in the GoF, but not the LOF group. The risk model predicted a >90% likelihood of non‐ambulation for individuals with GoF variants and seizure onset before 1 month of age, decreasing to ~35% with seizure onset after 20 months. Significance: We found a clear genotype–phenotype correlation in GABRB2‐ and GABRB3 ‐related disorders, demonstrating that GoF variants are associated with a more severe neurodevelopmental trajectory. The age at seizure onset serves as a biomarker for predicting motor outcomes in individuals with GoF variants. These findings provide guidance regarding prognosis, need for early intervention, and data for comparison of efficacy in targeted therapeutic interventions for GABA A receptor–related disorders.
Everolimus precision therapy in NPRL2‐ and NPRL3‐related epilepsy
Disinhibition of the mechanistic target of rapamycin (mTOR) pathway has been observed in patients with loss‐of‐function variants in the disheveled, Egl‐10, and pleckstrin domain‐containing protein 5 (DEPDC5), and nitrogen permease regulator‐like proteins 2 and 3 (NPRL2, and NPRL3) genes, which encode the components of GTPase activating protein Activity Toward Rags Complex 1 (GATOR1) complex. Everolimus, a synthetic mTOR inhibitor, has shown efficacy in treating seizures in patients with DEPDC5 epilepsy, but seemed to worsen seizures in the one published patient with NPRL3 epilepsy. We studied four patients with NPRL2‐ and NPRL3‐related epilepsies with intractable focal seizures treated with everolimus as add‐on therapy. Age at treatment initiation was between 1 month and 26 years; patients had baseline seizure frequencies ranging from 15 to 301 per month and had failed 6–14 antiseizure medications. Daily doses ranged between 3.75 and 11.5 mg with trough levels between 5 and 8.7 ng/mL. Two patients became seizure‐free by 2 months of treatment. In one of them, seizures recurred at levels below 4 ng/mL, and seizure freedom was regained with increased levels. The other two patients experienced a clinically meaningful seizure reduction of 52% and 86%, respectively. Two patients experienced stomatitis, resulting in everolimus discontinuation in one; one patient had hyperlipidemia and another had recurrent respiratory infections, which resolved with dose reduction. In conclusion, everolimus add‐on may be effective in substantially reducing seizures in patients with NPRL2‐ and NPRL3‐related epilepsies. However, strict surveillance is required, especially in young patients.
Everolimus precision therapy in NPRL2‐ and NPRL3‐related epilepsy
Disinhibition of the mechanistic target of rapamycin (mTOR) pathway has been observed in patients with loss‐of‐function variants in the disheveled, Egl‐10, and pleckstrin domain‐containing protein 5 (DEPDC5), and nitrogen permease regulator‐like proteins 2 and 3 (NPRL2, and NPRL3) genes, which encode the components of GTPase activating protein Activity Toward Rags Complex 1 (GATOR1) complex. Everolimus, a synthetic mTOR inhibitor, has shown efficacy in treating seizures in patients with DEPDC5 epilepsy, but seemed to worsen seizures in the one published patient with NPRL3 epilepsy. We studied four patients with NPRL2‐ and NPRL3‐related epilepsies with intractable focal seizures treated with everolimus as add‐on therapy. Age at treatment initiation was between 1 month and 26 years; patients had baseline seizure frequencies ranging from 15 to 301 per month and had failed 6–14 antiseizure medications. Daily doses ranged between 3.75 and 11.5 mg with trough levels between 5 and 8.7 ng/mL. Two patients became seizure‐free by 2 months of treatment. In one of them, seizures recurred at levels below 4 ng/mL, and seizure freedom was regained with increased levels. The other two patients experienced a clinically meaningful seizure reduction of 52% and 86%, respectively. Two patients experienced stomatitis, resulting in everolimus discontinuation in one; one patient had hyperlipidemia and another had recurrent respiratory infections, which resolved with dose reduction. In conclusion, everolimus add‐on may be effective in substantially reducing seizures in patients with NPRL2‐ and NPRL3‐related epilepsies. However, strict surveillance is required, especially in young patients.
- 30 June 2025
- Published by Wiley in Epileptic Disorders
- Vol. 27 (5) , 1011-1020
Epilepsy phenotype and developmental outcome in girls with mosaicism in X‐linked neurodevelopmental disorders
CDKL5 deficiency disorder (CDD) and SMC1A‐related epilepsy are X‐linked neurodevelopmental disorders characterized by early‐onset, mostly intractable epilepsy and severe intellectual disability. While recent advances in next‐generation sequencing improved diagnostic yields, detecting low‐frequency mosaicism remains challenging. We retrospectively analyzed the epilepsy and developmental phenotype of four female patients with mosaic CDKL5 or SMC1A variants. Clinical data, including seizure types, electroencephalographic findings, neurodevelopmental milestones, and genetic analyses, were reviewed. The two girls with CDKL5 mosaicism presented at 5 and 6 weeks with tonic seizures, rapidly developing hypermotor‐tonic‐spasms sequence seizures. Both achieved independent walking by age two and developed speech by 3 years. The two girls with SMC1A mosaicism presented clusters of focal impaired awareness, myoclonic, and tonic–clonic seizures at 19 and 20 months of age. They demonstrated milder intellectual disabilities, with one achieving normal speech and the other speaking over 100 words by age four. Both achieved independent walking, which is uncommon in germline patients. Girls with mosaic CDKL5 and SMC1A variants share the same epilepsy phenotype as the germline females but have milder intellectual and motor disabilities compared to germline patients. Recognizing specific seizure patterns may direct genetic testing, enabling earlier diagnosis and access to precision treatment.
- 30 June 2025
- Published by Wiley in Epileptic Disorders
- Vol. 27 (5) , 1011-1020
Epilepsy phenotype and developmental outcome in girls with mosaicism in X‐linked neurodevelopmental disorders
CDKL5 deficiency disorder (CDD) and SMC1A‐related epilepsy are X‐linked neurodevelopmental disorders characterized by early‐onset, mostly intractable epilepsy and severe intellectual disability. While recent advances in next‐generation sequencing improved diagnostic yields, detecting low‐frequency mosaicism remains challenging. We retrospectively analyzed the epilepsy and developmental phenotype of four female patients with mosaic CDKL5 or SMC1A variants. Clinical data, including seizure types, electroencephalographic findings, neurodevelopmental milestones, and genetic analyses, were reviewed. The two girls with CDKL5 mosaicism presented at 5 and 6 weeks with tonic seizures, rapidly developing hypermotor‐tonic‐spasms sequence seizures. Both achieved independent walking by age two and developed speech by 3 years. The two girls with SMC1A mosaicism presented clusters of focal impaired awareness, myoclonic, and tonic–clonic seizures at 19 and 20 months of age. They demonstrated milder intellectual disabilities, with one achieving normal speech and the other speaking over 100 words by age four. Both achieved independent walking, which is uncommon in germline patients. Girls with mosaic CDKL5 and SMC1A variants share the same epilepsy phenotype as the germline females but have milder intellectual and motor disabilities compared to germline patients. Recognizing specific seizure patterns may direct genetic testing, enabling earlier diagnosis and access to precision treatment.
- 27 July 2023
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 46, 89-97
A novel approach to seizures in neonates
- 27 July 2023
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 46, 89-97
A novel approach to seizures in neonates
- 21 March 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 100 (12) , E1234-E1247
Clinical and Neurophysiologic Phenotypes in Neonates With BRAT1 Encephalopathy
Background and Objective: BRAT1 encephalopathy is an ultra-rare autosomal recessive neonatal encephalopathy. We delineate the neonatal electroclinical phenotype at presentation and provide insights for early diagnosis. Methods: Through a multinational collaborative, we studied a cohort of neonates with encephalopathy associated with bi-allelic pathogenic variants in BRAT1 for whom detailed clinical, neurophysiological, and neuroimaging information was available from the onset of symptoms. Neuropathological changes were also analyzed. Results: We included nineteen neonates. Most neonates were born at term (16/19) from non-consanguineous parents. 15/19 (79%) were admitted soon after birth to a neonatal ICU, exhibiting multifocal myoclonus, both spontaneous and exacerbated by stimulation. 7/19 (37%) had arthrogryposis at birth, and all except one progressively developed hypertonia in the first week of life. Multifocal myoclonus, which was present in all but one infant, was the most prominent manifestation, and did not show any EEG correlate in 16/19 (84%). vEEG at onset was unremarkable in 14/19 (74%) infants, and 6 (33%) had initially been misdiagnosed with hyperekplexia. Multifocal seizures were observed at a median age of 14 days (range: 1-29). During the first months of life, all infants developed progressive encephalopathy, acquired microcephaly, prolonged bouts of apnea, and bradycardia, leading to cardiac arrest and death at a median age of 3.5 months (range: 20 days to 30 months). Only seven infants (37%) received a definite diagnosis before death, at a median age of 34 days (range: 25 to 126), and almost two-thirds (12/19, 63%) were diagnosed 8 days to 12 years post mortem (median: 6.5 years). Neuropathology examination, performed in 3 patients, revealed severely delayed myelination and diffuse astrogliosis, sparing the upper cortical layers. Discussion: BRAT1 encephalopathy is a neonatal-onset, rapidly progressive neurological disorder. Neonates are often misdiagnosed as having hyperekplexia, and many die undiagnosed. The key phenotypic features are multifocal myoclonus, an organized EEG, progressive, persistent, and diffuse hypertonia, and an evolution into refractory multifocal seizures, prolonged bouts of apnea, bradycardia, and early death. Early recognition of BRAT1 encephalopathy allows for prompt workup, appropriate management, and genetic counselling.
- 21 March 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 100 (12) , E1234-E1247
Clinical and Neurophysiologic Phenotypes in Neonates With BRAT1 Encephalopathy
Background and Objective: BRAT1 encephalopathy is an ultra-rare autosomal recessive neonatal encephalopathy. We delineate the neonatal electroclinical phenotype at presentation and provide insights for early diagnosis. Methods: Through a multinational collaborative, we studied a cohort of neonates with encephalopathy associated with bi-allelic pathogenic variants in BRAT1 for whom detailed clinical, neurophysiological, and neuroimaging information was available from the onset of symptoms. Neuropathological changes were also analyzed. Results: We included nineteen neonates. Most neonates were born at term (16/19) from non-consanguineous parents. 15/19 (79%) were admitted soon after birth to a neonatal ICU, exhibiting multifocal myoclonus, both spontaneous and exacerbated by stimulation. 7/19 (37%) had arthrogryposis at birth, and all except one progressively developed hypertonia in the first week of life. Multifocal myoclonus, which was present in all but one infant, was the most prominent manifestation, and did not show any EEG correlate in 16/19 (84%). vEEG at onset was unremarkable in 14/19 (74%) infants, and 6 (33%) had initially been misdiagnosed with hyperekplexia. Multifocal seizures were observed at a median age of 14 days (range: 1-29). During the first months of life, all infants developed progressive encephalopathy, acquired microcephaly, prolonged bouts of apnea, and bradycardia, leading to cardiac arrest and death at a median age of 3.5 months (range: 20 days to 30 months). Only seven infants (37%) received a definite diagnosis before death, at a median age of 34 days (range: 25 to 126), and almost two-thirds (12/19, 63%) were diagnosed 8 days to 12 years post mortem (median: 6.5 years). Neuropathology examination, performed in 3 patients, revealed severely delayed myelination and diffuse astrogliosis, sparing the upper cortical layers. Discussion: BRAT1 encephalopathy is a neonatal-onset, rapidly progressive neurological disorder. Neonates are often misdiagnosed as having hyperekplexia, and many die undiagnosed. The key phenotypic features are multifocal myoclonus, an organized EEG, progressive, persistent, and diffuse hypertonia, and an evolution into refractory multifocal seizures, prolonged bouts of apnea, bradycardia, and early death. Early recognition of BRAT1 encephalopathy allows for prompt workup, appropriate management, and genetic counselling.
- Open Access
- 27 January 2023
- Published by Elsevier in Clinical Neurophysiology
- Vol. 147, 99-107
Vagus nerve stimulation-induced laryngeal motor evoked potentials for response prediction and intensity titration in drug-resistant epilepsy
- 27 January 2023
- Published by Elsevier in Clinical Neurophysiology
- Vol. 147, 99-107
Open AccessVagus nerve stimulation-induced laryngeal motor evoked potentials for response prediction and intensity titration in drug-resistant epilepsy